Novo Nordisk A/S

Novo Nordisk supply of Wegovy stabilizes as new capacity comes online

FDA · weight loss · 4 min

Novo Nordisk says Wegovy supply is stabilizing as FDA-determined shortages of Wegovy and Ozempic are resolved. The company is also investing $4.1 billion to expand manufacturing capacity in Clayton, North Carolina.

Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends

FDA · weight-loss · 5 min

Novo Nordisk supply Wegovy stabilizes as the FDA says the shortage of Wegovy and Ozempic is resolved. The change follows new and planned manufacturing capacity, with implications for access, competition, and BD strategy.

Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst

EMA · oncology · 5 min

Novo Nordisk’s CagriSema Phase 3 program produced 22.7% mean weight loss in REDEFINE 1, reinforcing the program as a major obesity catalyst. This plan frames the results, the next clinical milestones, and why BD and investor teams should track them.

US FDA Proposes New Regulations on Weight-Loss Drug Compounding

FDA · weight loss · 2 min

The FDA has proposed new regulations limiting the mass compounding of weight-loss drugs from Novo Nordisk and Eli Lilly. This move could reshape the competitive landscape for these pharmaceutical giants.

AI Accelerates Novo Nordisk's Parkinson’s Cell Therapy

cell therapy · 3 min

Novo Nordisk is leveraging AI to enhance its Parkinson's cell therapy development. This advancement could reshape the market landscape for investors and analysts.